to this issue of Preventing Perinatal HIV Transmission: Field
Update. You are receiving this newsletter because you expressed an
interest in perinatal HIV prevention in hospitals or have signed up to
receive it. This quarterly email newsletter connects its subscribers to
news updates, trends, statistics, prevention programs, policy initiatives,
tools, and useful practices relating to perinatal HIV prevention in
U.S. hospitals. The Health Research and
Educational Trust (HRET), with support from the Centers for Disease
Control and Prevention (CDC), produces this newsletter as a forum for
information dissemination and for communication among and between hospital
staff, HIV experts, and researchers.
more information on HRET’s Perinatal HIV Prevention project, please visit
our web site.
you have comments or suggestions for future issues of this newsletter,
please contact Jennifer Reiter at email@example.com.
Testing Recommended for Patients in Healthcare
The Centers for Disease Control and
Prevention released on September 21 its recommendations on voluntary annual HIV screening for all
patients ages 13-64, citing in part the success of routinely screening
pregnant women to reduce mother-to-child transmission. Previously,
CDC guidelines had limited recommendations for routine counseling and
testing to people at high risk for HIV, in acute-care settings in which
HIV prevalence was greater than 1%, and all pregnant women.
Officials credit universal screening of pregnant women with helping
to reduce the annual number of infants born with HIV to fewer than 240
from a peak of 1,650 in 2001. To reduce mother-to-child transmission
even more, the new recommendations call for a second HIV test for pregnant
women in the third trimester in areas with high HIV prevalence among women
of childbearing age, in facilities with at least one HIV diagnosis per
1,000 pregnant women screened, and for women with HIV risk factors or
symptoms of acute HIV infection. The guidance also simplifies
testing procedures by no longer recommending pretest counseling and by
eliminating the recommendation for separate, written consent for HIV
testing. Instead, CDC recommends that consent for HIV testing be
incorporated into general consent for medical care.
Visit CDC’s HIV Testing in Healthcare
Settings web site for further supplementary materials including fact
sheets, podcasts, FAQs, and more.
HRET Develops Comparison Chart
of FDA-Approved Rapid HIV 1&2 Enzyme-Linked Immunosorbent Assays
(ELISA or EIAs)
The Perinatal HIV Prevention project at HRET
recently released a chart comparing FDA-approved HIV 1 and 2 ELISA or EIA
tests currently available for purchase.
Click here to view the chart. This chart is a
companion to previously released information on rapid HIV screening tests.
If you would like further
information on any of the products summarized on the charts, please
contact the listed manufacturers directly.
Creates Map of Jurisdictions with Elevated Incidence of HIV or AIDS Among
Women aged 15-45 Years (2004)
The CDC recently released its recommendations
for HIV testing of adults, adolescents, and pregnant women in healthcare
settings. On page nine of this document, there are 17
jurisdictions listed which, based on the latest data, have elevated
incidence of HIV or AIDS among women aged 15-45. HRET developed a
map in order to encourage state, regional, and metropolitan association
executives to work with their public health department and healthcare
providers to ensure third trimester HIV testing among pregnant
here to access the map created by HRET on these
Launches Redesigned Perinatal Web Site
The CDC perinatal HIV prevention website has
recently been completely overhauled. Statistics and information have
been updated, a greater emphasis on the national organizations has been
added, and a new section for the general public provides valuable
information to a wider audience about preventing mother to child
transmission. Visit their web site here.
Releases Updated State HIV Testing Laws
The National HIV/AIDS Clinicians’ Consultation
Center (NCCC) has released its
updated State HIV Testing Laws Compendium highlighted on its web site. This
compendium describes each state’s policies, rules, and regulations on HIV
testing and provides state-by-state comparisons. Understanding individual states’
HIV testing laws can be essential when providing testing and counseling
for patients and in implementing HIV testing programs. The compendium will become
increasingly important as HIV testing becomes more routine.
Additional help on HIV testing and state laws
can be obtained by calling the NCCC’s expert HIV Telephone Consultation
Service (Warmline) at (800) 933-3413. The NCCC also provides advice on occupational
exposures to blood-borne pathogens on its PEPline at (888) 448-4911, and
advice on managing HIV in pregnant women and their infants on its
Perinatal Hotline at (888) 448-8765. These free consultation services are
for healthcare workers only. Additional HIV training and
education is available through the regional AIDS Education and Training Centers (AETCs) on their web site. The NCCC is based at the University of
California San Francisco/San Francisco General
Hospital and is part of the Health Resources
and Services Administration (HRSA) AETC program, in collaboration with the
Centers for Disease Control and Prevention (CDC).
A more abridged compendium of state laws on HIV
testing appears on the HRET web site as well.
Resource on Counseling HIV-Infected Individuals Who Want to Have
This overview, authored by Arthur Ammann, MD, discusses
issues to consider when providing reproductive counseling for HIV-infected
concordant and discordant couples, including antiretroviral treatment, and
the risk of reinfection or superinfection, risk reduction practices,
adoption, sperm washing and insemination, and artificial insemination
using an HIV-uninfected donor. The document, which was developed by
the UCSF Center for HIV Information, targets doctors/physicians, nurses,
physician assistants/nurse practitioners, midwives, and counselors.
To view the document, click here.
Releases Sexually Transmitted Diseases Treatment
These guidelines for the treatment of patients
who have sexually transmitted diseases (STDs) were developed by CDC after
consultation with a group of professionals knowledgeable in the field of
STDs who met in Atlanta during April 19-21, 2005. The information in this report
updates the Sexually Transmitted Diseases Treatment Guidelines, 2002 (MMWR
2002;51[No. RR-6]). Included
in these updated guidelines are an expanded diagnostic evaluation for
cervicitis and trichomoniasis; new antimicrobial recommendations for
trichomoniasis; additional data on the clinical efficacy of azithromycin
for chlamydial infections in pregnancy; discussion of the role of
Mycoplasma genitalium and trichomoniasis in urethritis/cervicitis and
treatment-related implications; emergence of lymphogranuloma venereum
protocolitis among men who have sex with men (MSM); expanded discussion of the criteria for
spinal fluid examination to evaluate for neurosyphilis; the emergence of
azithromycin resistant-Treponema pallidum; increasing prevalence of
quinolone-resistant Neisseria gonorrhea in MSM; revised discussion concerning the
sexual transmission of hepatitis C; postexposure prophylaxis after
sexual assault; and an expanded discussion of STD prevention approaches.
To view the document, click here.
View On Line Version